- Home
- SPCE vs XFOR Comparison
SPCE vs XFOR Comparison
Compare SPCE & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- XFOR
- Stock Information
- Founded
- SPCE 2017
- XFOR 2014
- Country
- SPCE United States
- XFOR United States
- Employees
- SPCE N/A
- XFOR N/A
- Industry
- SPCE Transportation Services
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPCE Consumer Discretionary
- XFOR Health Care
- Exchange
- SPCE Nasdaq
- XFOR Nasdaq
- Market Cap
- SPCE 148.0M
- XFOR 118.4M
- IPO Year
- SPCE N/A
- XFOR N/A
- Fundamental
- Price
- SPCE $2.90
- XFOR $2.11
- Analyst Decision
- SPCE Hold
- XFOR Strong Buy
- Analyst Count
- SPCE 4
- XFOR 3
- Target Price
- SPCE $13.06
- XFOR $72.33
- AVG Volume (30 Days)
- SPCE 3.9M
- XFOR 376.4K
- Earning Date
- SPCE 08-06-2025
- XFOR 08-07-2025
- Dividend Yield
- SPCE N/A
- XFOR N/A
- EPS Growth
- SPCE N/A
- XFOR N/A
- EPS
- SPCE N/A
- XFOR 2.16
- Revenue
- SPCE $5,512,000.00
- XFOR $31,364,000.00
- Revenue This Year
- SPCE N/A
- XFOR $1,106.53
- Revenue Next Year
- SPCE $4,110.27
- XFOR N/A
- P/E Ratio
- SPCE N/A
- XFOR $0.97
- Revenue Growth
- SPCE N/A
- XFOR N/A
- 52 Week Low
- SPCE $2.18
- XFOR $2.05
- 52 Week High
- SPCE $9.23
- XFOR $30.90
- Technical
- Relative Strength Index (RSI)
- SPCE 41.43
- XFOR 28.84
- Support Level
- SPCE $2.84
- XFOR $2.62
- Resistance Level
- SPCE $3.02
- XFOR $2.98
- Average True Range (ATR)
- SPCE 0.22
- XFOR 0.35
- MACD
- SPCE -0.04
- XFOR -0.07
- Stochastic Oscillator
- SPCE 6.42
- XFOR 2.47
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures advanced air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.